![CEimpact Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5e/ae/42/5eae4208-b706-0adc-12fb-75292fc9ea63/mza_14075584767013252581.jpg/100x100bb.jpg)
Fluvoxamine to Treat COVID-19?
CEimpact Podcast
English - November 15, 2021 10:00 - 30 minutes - 20.8 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
The TOGETHER Study, published in Lancet, evaluated the role of fluvoxamine in the treatment of COVID-19. Is this a real GameChanger, or just another dud? Lay media has been picking up the study - listen to Geoff and Jake break down the article to help healthcare providers give evidence-based recommendations.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
Need a membership?
References and resources: Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27:S2214-109X(21)00448-4. doi: 10.1016/S2214-109X(21)00448-4. Epub ahead of print. PMID: 34717820; PMCID: PMC8550952.
Additional Resources:
WSJ Opinion on Fluvoxamine
WSJ Letter-to-Editor
Continuing Education Information:
Learning Objectives:
1. Describe the inclusion and exclusion criteria for the TOGETHER study
2. Discuss the role of Drug-Drug Interactions with fluvoxamine
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-394-H01-P
Initial release date: 11/15/21
Expiration date: 11/15/22
Dr. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here